Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00453700 · ClinicalTrials.gov registry record

Prevalence of Chagas Disease in Immigrant Patients With Conduction Abnormalities on Electrocardiogram

A clinical trial, sponsored by Olive View-UCLA Education & Research Institute.

Completed
Registry status
327
Enrollment target

NCT00453700 is a clinical trial that has completed, run by Olive View-UCLA Education & Research Institute. The registered enrollment target is 327 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00453700 has completed, sponsored by Olive View-UCLA Education & Research Institute.

COMPLETED
Registry status
327 participants
Enrollment target

Study Summary

Chagas disease is endemic to the Americas, infecting between 16-18 million individuals. In immigrant populations in the United States from endemic areas, it is estimated up to 4.9% may be asymptomatic carriers of Trypanosoma cruzi, the organism which causes Chagas disease. Between 10-20% of these patients progress to development of end-stage cardiomyopathy with a high associated morbidity. Following acute disease, patients enter into an indeterminate phase which can last 10-20 years. The earliest sign of cardiac involvement usually is electrocardiogram abnormalities. The most common abnormality is right bundle branch block (RBBB), followed by left anterior fascicular block (LAFB), and left bundle branch block (LBBB). Recent studies have shown that treatment of patients at this stage with antiparasitics may delay the progression of overt cardiomyopathy. At the University of California, Los Angeles, there is a large population of immigrant patients from countries endemic to Chagas disease. The researchers propose that screening patients with conduction abnormalities on electrocardiogram may be a potentially useful method to identify patients with early cardiac manifestations of Chagas disease. The researchers hope to enroll approximately 300 individuals with RBBB, LAFB or LBBB on electrocardiogram to determine the incidence of Chagas disease in this patient population.

Interventions

  • PROCEDURE Trypanosoma cruzi serology

Trial Details

FieldValue
Enrollment Target 327 participants
Start Date 2007-01
Est. Completion 2010-12

What the Registry Record Tells You About NCT00453700

The ClinicalTrials.gov registry entry for NCT00453700 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 327 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Olive View-UCLA Education & Research Institute, which has 11 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Trypanosoma cruzi serology is the first listed.

NCT00453700 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00453700 about?

NCT00453700 is a clinical study titled "Prevalence of Chagas Disease in Immigrant Patients With Conduction Abnormalities on Electrocardiogram". Chagas disease is endemic to the Americas, infecting between 16-18 million individuals. In immigrant populations in the United States from endemic areas, it is estimated up to 4.9% may be asymptomatic carriers of Trypanosoma cruzi, the organism which causes Chagas disease. Between 10-20% of these pa...

What is the current status of trial NCT00453700?

This trial is currently completed. The enrollment target is 327 participants. The study started on 2007-01. Estimated completion is 2010-12.

What interventions are being tested in trial NCT00453700?

The interventions under investigation include: Trypanosoma cruzi serology (PROCEDURE).

Who is sponsoring clinical trial NCT00453700?

This trial is sponsored by Olive View-UCLA Education & Research Institute, which has 11 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.